Hansa Biopharma Reports Second Quarter and First Half Year 2026 Financial Results

Hansa Biopharma AB* €115 million out-licensing agreement * Positive data from European confirmatory trial (PAES) Lund, Sweden, 22 July 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced its half year report for the period January-June 2026.

Renée Aguiar-Lucander, CEO, Hansa Biopharma said, “This was a defining quarter for Hansa. The announcement of the European out-licensing agreement, positive PAES results supporting application for conversion to full European approval, growing recognition of the strength and clinical relevance of our ConfIdeS Phase 3 data, and continued progress toward a potential US launch of imlifidase mark important milestones in our development. These achievements strengthen our financial foundation, increase our strategic flexibility, and reinforce our confidence in the significant long-term opportunity for imlifidase to transform outcomes for highly sensitized kidney transplant patients.”